Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer

William M. Merritt1, Alpa M. Nick1, Amy R. Carroll1, Chunhua Lu1, Koji Matsuo1, Melissa Dumble5, Nicholas Jennings1, Shu-Yun Zhang5, Yvonne G. Lin1, Whitney A. Spannuth1, Aparna A. Karnat1, Rebecca L. Stone1, Mian M.K. Shahzad4, Robert L. Coleman1, Rakesh Kumar5, and Anil K. Sood1,2,3

Abstract
This study aimed to investigate the antitumor and antiangiogenic effects utilizing a novel therapy regimen of metronomic topotecan and pazopanib, a multireceptor tyrosine kinase inhibitor. In vitro (Western blot) and in vivo dose-finding experiments were done following pazopanib therapy in ovarian cancer models. Pazopanib and metronomic (daily) oral topotecan therapy was examined in an orthotopic model of ovarian cancer. Tumor weights, survival, and markers of the tumor microenvironment [angiogenesis (CD31 and pericyte coverage), proliferation (Ki-67), and apoptosis (terminal deoxynucleotidyl transferase–mediated dUTP nick-end labeling)] were analyzed by immunostaining following therapy. Pazopanib therapy reduced vascular endothelial growth factor receptor 2 (VEGFR-2) activity in vitro and in vivo in a dose-dependent manner. Compared with control mice, pazopanib reduced tumor weight by 28% to 82% (P < 0.01 in the SKOV3ip1 model) and metronomic topotecan reduced tumor weight by 40% to 59% in the HeyA8 (P = 0.13) and SKOV3ip1 (P = 0.07) models. Combination therapy had the greatest effect with 79% to 84% reduction (P < 0.01 for both models). In the SKOV3ip1 and A2780 models, mouse survival was significantly longer (P < 0.001 versus controls) with pazopanib and metronomic topotecan therapy. Pazopanib therapy reduced murine endothelial cell migration in vitro in a dose-dependent manner following VEGF stimulation and decreased tumor microvessel density and pericyte coverage when given in combination with metronomic topotecan. Tumor cell proliferation decreased in all treatment arms compared with controls (P < 0.01 for combination groups) and increased tumor cell apoptosis by 4-fold with combination therapy. Pazopanib therapy in combination with metronomic topotecan therapy showed significant antitumor and antiangiogenic properties in preclinical ovarian cancer models and warrants further investigation as a novel therapeutic regimen in clinical trials. Mol Cancer Ther; 9(4): 985–95. ©2010 AACR.

Introduction
Surgical debulking followed by cytotoxic therapy is currently the standard of care for patients with ovarian carcinoma. Unfortunately, despite such aggressive therapy, most patients develop recurrence and die from progressive disease. Over the past decade, numerous novel biological agents have been developed and investigated as the next step towards curing this deadly disease. One of the most attractive targets for biological agents is tumor vasculature or angiogenesis. Folkman first introduced concepts regarding the requirement of angiogenesis for tumor growth in 1971 (1). Since then, a clearer understanding of the process of angiogenesis has emerged, which has contributed to the development of novel therapeutic approaches (2).

Traditional cytotoxic regimens generally employ chemotherapeutic agents that are administered to patients at, or near, the highest dose that can be safely given. The contemporary management for ovarian cancer is no exception, with most patients receiving combination platinum and taxane as primary chemotherapy for advanced-stage disease (3). More than 80% of patients with ovarian cancer will initially respond to this strategy; however, most will eventually develop chemoresistant disease. Moreover, treatment-limiting toxicities acutely and chronically challenge the combination of agents dosed in this manner. An alternative strategy involves...
lower, more frequent dosing of the cytotoxic agent, i.e., metronomic therapy (4). The theory underlying this approach relates to less host toxicity than, but similar tumor cell kill as traditional dosing schedules. Several studies have reported success with metronomic therapy in preclinical and clinical models (5–7). Furthermore, metronomic therapy also shows antiangiogenic properties secondary to continued exposure on tumor endothelial cells (8, 9). On the basis of Hif-1α inhibition, we recently reported that metronomic topotecan had similar antitumor activity compared with the traditionally maximally tolerated dosing and significantly decreased tumor vascularity in murine models of advanced ovarian cancer (10). We hypothesized that metronomic topotecan would result in greater antitumor activity in combination with other antiangiogenic agents. The antitumor and antiangiogenic benefits of vascular endothelial growth factor (VEGF)-targeted therapy are promising and offer opportunities for further investigation. VEGF and its receptors (VEGFR-1, -2, and -3) are commonly expressed in human cancers and have been identified as optimal angiogenic targets (11). In addition to increased expression, VEGF receptors are also associated with poor prognosis in multiple cancer types, including ovarian cancer (12–15). Based on our earlier results with metronomic topotecan (10), we explored in the current study the antitumor and antiangiogenic efficacy of metronomic topotecan with a multireceptor kinase inhibitor, pazopanib, in ovarian cancer models.

Materials and Methods

Cell lines and reagents

The derivation and source of the human epithelial ovarian cancer cell lines HeyA8, SKOV3ip1, and A2780, and the murine ovarian endothelial cell line (MOEC) have been described previously (16, 17). Cell lines were maintained and propagated in RPMI-1640 medium supplemented with 15% fetal bovine serum and 0.1% gentamicin sulfate (Gemini Bioproducts). All experiments were done using cells grown to 60% to 80% confluence, and all cell lines were routinely tested to confirm the absence of Mycoplasma.

Pazopanib (GlaxoSmithKline) was mixed in DMSO (Sigma) for all in vitro experiments and 0.5% hydroxypropylmethylcellulose (Sigma) and 0.1% Tween-80 (Sigma) diluted in water for in vivo therapy. Topotecan (GlaxoSmithKline) was prepared and stored in 10 mmol/L Tri-HCl (pH 4.0) aliquots prior to being diluted in water for oral therapy in vivo.

In vivo orthotopic ovarian cancer model

Female athymic nude mice were purchased from the National Cancer Institute-Frederick Cancer Research and Development Center (Frederick, MD) or Taconic Farms (Hudson, NY) and housed in specific pathogen-free conditions. They were cared for in accordance with the guidelines set forth by the American Association for Accreditation for Laboratory Animal Care and the U.S. Public Health Service’s Policy on Human Care and Use of Laboratory Animals, and all studies were approved and supervised by the Institutional Animal Care and Use Committee at either M.D. Anderson Cancer Center or GlaxoSmithKline. The ovarian cancer cell lines were maintained and prepared for in vivo i.p. injection as previously described for the orthotopic model by our group (17). For the A2780 survival experiment, 10 million cells were injected i.p. 1 wk prior to initiation of treatment.

In vivo pazopanib and topotecan therapy

To determine the optimal pazopanib dose for future experiments, SKOV3ip1 tumor-bearing mice were treated with either 30 or 100 mg/kg pazopanib daily for 3 d. Mice were sacrificed at 4, 24, 48, and 72 h following 72 h of therapy. Tumors were snap frozen in optimal cutting medium (Miles, Inc.) for immunofluorescence analysis.

For the HeyA8 and SKOV3ip1 therapy models, the mice were randomly separated and assigned to treatment groups (n = 10/group) approximately 1 wk after cell line inoculation. Treatment groups were control (vehicle only), metronomic topotecan (0.5 mg/kg, oral, daily, dose established in ref. 10), pazopanib (100 mg/kg, oral, every other day), and topotecan plus pazopanib (same doses used in single-treatment arms). Therapy was continued until mice became moribund in any of the treatment groups. All treatment groups were then sacrificed by cervical dislocation, and tumor and mouse weights were recorded. Representative tumor specimens were collected from each treatment group and stored for further immunohistochemical analyses.

To determine the survival benefit of metronomic topotecan and pazopanib, experiments were carried out using the SKOV3ip1 and A2780 cell line models. Mice were inoculated i.p. with either SKOV3ip1 or A2780 cells as in the therapy models. In the SKOV3ip1 model, the mice (n = 10/group) were treated with similar regimens as in the previous therapy experiment. In the A2780 model, the mice (n = 10/group) were treated with the following regimens: vehicle 1 (hydroxypropylmethylcellulose/Tween), vehicle 2 (tartaric acid), pazopanib 100 mg/kg (oral, twice daily), maximum tolerated dose (MTD) topotecan 5 mg/kg (i.v., daily × 5 d every 21 d), MTD topotecan 10 mg/kg (i.v., every 7 d × 3 doses), metronomic topotecan 1 mg/kg (oral, daily), pazopanib plus topotecan 5 mg/kg, pazopanib plus topotecan 10 mg/kg, or pazopanib plus metronomic topotecan 1 mg/kg. Mice were sacrificed (recorded as date of death) when they appeared significantly moribund as determined by investigator and animal care veterinarians.

Western blot assay for VEGFR-2/phospho-VEGFR-2

To determine whether pazopanib or topotecan inhibited phosphorylation of VEGFR-2 in ovarian cancer cells, SKOV3ip1 and HeyA8 cells were serum starved for 24 h and then treated with either pazopanib (0.001–100 μmol/L) for approximately 3 to 4 h or topotecan (6.25–100 nmol/L) for 12 h. In the pazopanib assay,
VEGF-A (10 ng/mL; Invitrogen) was added 1 h prior to collecting cell lysates. In both assays, cell lysates were collected in radioimmunoprecipitation assay lysis buffer (50 mmol/L Tris, 150 mmol/L NaCl, 1% Triton, 0.5% deoxycholate plus 25 μg/mL Leupeptin, 10 μg/mL apro- tinin, 2 mmol/L EDTA, 1 mmol/L sodium orthovanadate), centrifuged at 13,500 rpm for 15 min at 4°C, and protein concentration was determined using a Bio-Rad Protein Assay Kit (Bio-Rad). Protein bands were separated by 10% SDS-PAGE and transferred to nitrocellu- lose paper, blocked with 5% milk for 2 h at room temperature, incubated with either rabbit anti-human VEGFR-2 antibody Tyr (Santa Cruz Biotechnology) or rabbit anti-human phospho-VEGFR 2/3 (Calbiochem) overnight at 4°C followed by incubation with appro- priate secondary anti-rabbit horseradish peroxidase (HRP)-conjugated antibody for 2 h at room temperature. Blots were developed with the ECL Western Blot- ting Detection Kit (GE Healthcare). Actin was used for loading control, and all experiments were repeated in duplicate. Densitometry was done to analyze phos- phorylation levels.

**Migration assay**

To determine the effects of inhibiting VEGFR-2 activity on murine endothelial cell or ovarian cancer cell migra- tion, 1 × 10⁵ viable MEOCs or SKOV3ip1 cells (deter- mined by trypsin blue exclusion) were resuspended in serum-free media and plated onto a 0.1% gelatin-coated membrane matrix using a membrane culture system (MICS) as previously described (17). Prior to placement into the MICS system, cells were maintained in serum- free media for approximately 12 h and then treated with pazopanib (0.001, 1, and 10 μmol/L) for 4 to 5 h followed by addition of VEGF-A (10 ng/mL; Invitrogen) 1 h prior to placement into MICS top wells. The bottom wells were filled with serum-free media and VEGF-A (Invitrogen). Chambers were incubated for 8 h at 37°C. At completion, cells in the bottom chambers were removed and quantified (5 random fields/well) as a percentage of mi- grated cells/1 × 10⁶ cells plated as previously described (17). Experiments were done in duplicate.

**Immunohistochemistry**

Immunofluorescent staining of VEGFR-2 was done on 4-μm-thick frozen orthotopic ovarian cancer specimens. After hydration in cold acetone for 10 min, endogenous peroxidases were blocked with 3% hydrogen peroxide followed by primary antibody incubation, phospho-VEGFR2/3 (Calbiochem) overnight at 4°C. The following day, slides were washed and incubated with appropriate antirabbit secondary antibody. Images were taken using a Zeiss Axioplan2 microscope (Carl Zeiss, Inc.) with a Hamamatsu ORCA-ER camera (Hamamatsu Photonics) and captured with ImagePro Plus software v5.1 (Media- Cybernetics). Immunohistochemical analyses of CD31 (primary antibody: rat monoclonal anti-mouse, 1:800 dilution, BD Bioscience, Pharmingen) and terminal deoxy- nucleotidyl transferase–mediated dUTP nick-end label- ing (TUNEL) were conducted on orthotopic specimens as described previously (17). Ki-67 staining was done on paraffin-embedded slides. Slides were washed and hydrated with sequential washes in ethanol, blocked with 5% normal horse/1% normal goat serum in PBS. Following overnight incubation with Ki-67 rabbit polyclonal anti-human antibodies (1:200 dilution; BioCare Medical) at 4°C, the slides were washed with PBS, incubated with appropriate goat anti-rabbit HRP secondary antibody at 4°C for 4 h, and then antibody detection was done following incubation with 3,3′-diaminobenzidine substrate for 10 min. For pericyte coverage analysis, dual immunohistochemical staining for CD31 and α smooth muscle actin (αSMA) was done on paraffin sections. Fol- lowing antigen retrieval with citrate buffer, sections were incubated with αSMA antibody (Abcam) overnight at 4°C and then with HRP-conjugated IgG (Jackson ImmunoResearch) for 1 h at room temperature. Slides were then stained with 3,3′-diaminobenzidine, washed, and incubated with CD31 antibody (BD Bioscience) overnight at 4°C, followed by incubation with rat probe and HRP polymer (BioCare). Lastly, the slides were stained with Ferangi Blue Chromogen (BioCare). Quantification of microvessel density (CD31), tumor cell proliferation (Ki-67), apoptosis (TUNEL), and pericyte coverage was done on slides from each treatment group, as previously described (17, 18). Images were taken with a Nikon Micro- phot-FXA microscope (Nikon Instruments) and a Leica DFC-320 camera (Leica Microsystems) and captured with ImagePro Plus v5.1.

**Statistical analysis**

For animal experiments, 10 mice were assigned per treatment group. This sample size gave 80% power to de- tect a 50% reduction in tumor weight at a 5% level of sta- tistical significance. Mouse and tumor weights and the number of tumor nodules for each group were compared using Student’s t-test (for comparisons of two groups) and ANOVA (for multiple group comparisons). Normal- ity of weight distributions was tested by Kolmogrov- Smirnov test. Kaplan-Meier survival curves and log-rank test were used to determine relationships between thera- py regimens and mouse survival. All statistical tests were two-sided and P < 0.05 was considered statistically significant. All statistical analyses were carried out using SPSS version 12 for Windows statistical software (SPSS, Inc.).

**Results**

In vitro and in vivo effects of pazopanib therapy on VEGFR

Prior to initiating in vivo therapy experiments, we tested the effects of pazopanib and topotecan on VEGFR-2 ex- pression and phosphorylation in ovarian cancer cells. In vitro, SKOV3ip1 and HeyA8 cells were treated with
a range of pazopanib concentrations followed by stimulation with VEGF. The total VEGFR-2 expression was not affected by pazopanib therapy; however, VEGFR-2 phosphorylation decreased at low doses but this was more apparent at higher doses, ≥1 μmol/L doses in the SKOV3ip1 cell line (Fig. 1A). In HeyA8 cells, pazopanib therapy also decreased VEGFR-2 phosphorylation, but at higher doses compared with the SKOV3ip1 cells (data not shown). Topotecan treatment alone had no effect on VEGFR-2 phosphorylation in SKOV3ip1 and HeyA8 cells (Supplementary Fig. S1). In vivo, tumor-bearing mice were treated with two different doses of oral pazopanib. Mice were sacrificed at different time points, and harvested tumors were examined for VEGFR-2 phosphorylation. As early as 4 hours after treatment, a noticeable decrease in VEGFR-2 phosphorylation on tumor cells was observed in mice treated with pazopanib at 100 mg/kg compared with controls (Fig. 1B). Modulation of phosphorylated VEGFR-2 expression was still evident up to 48 hours following treatment until returning to baseline at 72 hours. The lower pazopanib dose (30 mg/kg) showed no observable effect on VEGFR-2 phosphorylation (data not shown).

Effect of metronomic topotecan and antiangiogenesis therapy in an orthotopic ovarian cancer model

To determine the effects of pazopanib on ovarian cancer growth, we did therapy experiments with oral pazopanib therapy alone and in combination with metronomic topotecan in the HeyA8 and SKOV3ip1 orthotopic murine cancer models. Study arms (n = 10 mice/arm) included control (vehicle only, 100 μL oral gavage daily), pazopanib (100 mg/kg diluted in 100 μL oral gavage every other day), topotecan (0.5 mg/kg diluted in 100 μL oral gavage daily), and combination (pazopanib and topotecan, same doses as single-agent therapy). Single-agent pazopanib therapy reduced mean tumor weight by 28% (versus controls, P = 0.22) and 82% (P = 0.007) in the HeyA8 and SKOV3ip1 models, respectively (Fig. 2). Consistent with our previous report, metronomic topotecan therapy reduced mean tumor weights by 40% (HeyA8, P = 0.13) and 59% (SKOV3ip1, P = 0.07).
compared with mice treated with vehicle only. The greatest reduction in tumor weight was observed in mice treated with combination therapy. When compared with controls, a 79% to 84% (P < 0.01 for both models) reduction was noted with pazopanib and metronomic topotecan. In comparison with single-agent therapy in the HeyA8 model, combination therapy inhibited tumor growth by 70% (versus pazopanib, P < 0.01) and 64% (versus metronomic topotecan, P = 0.22). In the SKOV3ip1 model, single-agent pazopanib therapy exhibited similar antitumor activity as combination therapy (12% difference in mean tumor weight, P = NS). No differences in eating/drinking habits, mouse activity, and mean mouse weights were noted between treatment groups in both models, suggesting minimal toxicity from administered agents.

On the basis of encouraging efficacy data, we next examined the effects of metronomic topotecan and antiangiogenesis treatment on animal survival. For these experiments, mice inoculated with either SKOV3ip1 or A2780 cells were treated with regimens as described above until the mice became moribund, as determined by primary investigators or animal staff. In the SKOV3ip1 model, single-agent pazopanib and metronomic topotecan therapy prolonged mouse survival compared with controls; however, the greatest effect was observed in the combination therapy arm (P < 0.001 versus all other groups; Fig. 3A). To validate these findings, a separate survival experiment was carried out using the A2780 model in a separate laboratory. The design included an expanded treatment regimen of single-agent pazopanib, MTD or metronomic dosing as well as combination therapy with both agents. As illustrated in the Kaplan-Meier curve (Fig. 3B), single-agent metronomic topotecan therapy was similar to single-agent pazopanib. MTD dosing was superior to metronomic topotecan; however, when metronomic topotecan was combined with pazopanib therapy, survival was noticeably superior to other groups (P < 0.001 versus pazopanib alone; P = 0.09 versus MTD topotecan 10 mg/kg plus pazopanib arm).

**Antiangiogenic properties of pazopanib therapy**

Based on the prior evidence that pazopanib therapy targets tumor vasculogenesis (19), we first examined whether the pazopanib therapy directly affected murine endothelial cells in vitro (Fig. 4A). Following pazopanib treatment, migration of MOECs was analyzed after stimulation with VEGF. VEGF alone increased endothelial cell migration (90%) compared with untreated cells. With the addition of pazopanib therapy, migration of MOECs decreased in a dose-dependent manner with concentrations ranging from 0.001 μmol/L to 10 μmol/L (28–61% reduction versus VEGF stimulated cells; P < 0.05 for 1 and 10 μmol/L doses).

With the known antiangiogenic activity of both pazopanib and metronomic topotecan, we analyzed the
tumors from both treatment experiments for microvessel density (MVD) and pericyte coverage. In the HeyA8 model, pazopanib and metronomic topotecan alone reduced MVD by 24% (P = 0.07) and 29% (P = 0.01), respectively (Fig. 4B). In the SKOV3ip1 tumors, both single-agent therapies significantly reduced MVD (pazopanib at 46% reduction versus controls, P = 0.03; topotecan at 34% reduction, P = 0.04; Fig. 4B and C). The greatest decrease in MVD paralleled the effects observed with tumor weights using combination therapy in the HeyA8 (66% decrease, P < 0.001) and SKOV3ip1 (50%, P = 0.002) models. The effects of therapy on vessel maturation were examined by assessing the extent of pericyte coverage (Fig. 4D). No differences were observed in tumors between the control group and mice treated with metronomic topotecan. However, single-agent pazopanib and combination therapy led to a significant decrease in pericyte coverage compared with controls (P < 0.05).

**Alterations in tumor microenvironment with pazopanib and topotecan therapy**

To determine the effects of pazopanib and metronomic therapy on other critical components of the tumor microenvironment, we examined tumor cell migration, proliferation, and apoptosis. Following treatment with pazopanib, SKOV3ip1 cell migration decreased by 68% (P < 0.01 compared with controls; Supplementary Fig. S2). Examination of tumors from the in vivo therapy experiments showed that single-agent pazopanib therapy reduced tumor cell proliferation in the SKOV3ip1 (P < 0.001; Fig. 5A) and HeyA8 (P = 0.18; Fig. 5A and B) models compared with controls. Metronomic topotecan therapy was effective in both SKOV3ip1 (14% reduction versus controls, P = 0.085) and HeyA8 (19%, P = 0.35) models. Combination therapy exhibited the greatest effect over controls with 22% to 42% reduction (P < 0.01).

Tumor cell apoptosis was examined in tumors from the HeyA8 therapy experiment by TUNEL immunofluorescence analysis (Fig. 5C). Single-agent therapy increased tumor cell apoptosis by 1.8-fold (P = 0.06) and 1.9-fold (P = 0.05) in the pazopanib and topotecan arms, respectively. Combination therapy significantly increased apoptosis (4.1-fold versus controls, P = 0.001) and remained superior when compared with other single-agent therapies (P < 0.05 for both regimens).

**Discussion**

The key findings of this study are that pazopanib therapy effectively inhibits VEGFR-2 activity, and results in significant reduction in tumor growth and angiogenesis in combination with metronomic topotecan. Furthermore, combination therapy led to prolonged mouse survival compared with controls and single-agent regimens. These effects likely reflect the antiangiogenic properties of both agents.

Tumor angiogenesis is led by an increase in proangiogenic factors, predominantly driven by VEGF and its receptors (20). The predominant ligand for VEGFRs, VEGF-A, is reported to provide a paracrine loop between tumor cells and endothelial cells expressing high VEGFR-2 levels (20). VEGFR-2 stimulation leads to vasculogenesis in embryonic development and increased endothelial cell migration, proliferation, and tubule formation in tumor vasculature (21–23). Moreover, high expression of VEGFRs in tumor and endothelial cells supports the basis of anti-VEGFR-targeted cancer therapy (15, 24–26). Recently, we reported that inhibition of host and tumor VEGFR-2 activity decreased tumor growth and angiogenesis in a murine model of advanced ovarian carcinoma (15). Others have reported similar findings with VEGFR-2 blockade in ovarian carcinoma (27, 28). These and other reports led us to investigate the efficacy of...
targeting VEGFR-2 utilizing a small molecular tyrosine kinase inhibitor, pazopanib, in orthotopic ovarian cancer models.

The combination of biological agents and cytotoxic therapy is a unique and more recently proposed method for treating cancer patients. In the current study, we chose to test the effects of metronomic therapy with oral topotecan in combination with pazopanib. Pazopanib is a potent angiogenic small molecule inhibitor of the tyrosine kinases VEGFR-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR), and c-kit (19, 29, 30). We and others have shown that pazopanib therapy reduces endothelial cell proliferation and migration (19). The effects of VEGFR-2 inhibition in ovarian tumor cells has also been reported. For example, Spannuth et al. reported that ovarian cancer cell migration was reduced using a monoclonal antibody targeting VEGFR-2 (15). Here, we show similar findings following pazopanib

Figure 4. Antiangiogenic effects of pazopanib therapy. A, murine endothelial cell migration in vitro following pazopanib therapy with VEGF stimulation. Bars, SD. *, P < 0.05 versus VEGF-treated cells. B, microvessel density analyses of HeyA8 (left) and SKOV3ip1 (right) tumors following pazopanib (paz) and metronomic topotecan (topo) therapy. C, representative photographs of CD31 staining in SKOV3ip1 tumors (original magnification ×100). D, pericyte coverage analysis of SKOV3ip1 tumors. Bars, SE. *, P < 0.05 versus control. δ, P < 0.05 versus all other groups.
therapy. VEGFR-2 phosphorylation in the SKOV3ip1 and HeyA8 cell lines was reduced following treatment with pazopanib; however, there were differences between these cell lines with regard to the dose required to reduce phosphorylation. These findings would suggest that pazopanib not only affects endothelial cells, but may also have direct effects on tumor cells. Pazopanib has also been shown effective in previous phase I, II, and III clinical trials (29, 31, 32). For example, in a large study of 225 patients with advanced or metastatic renal cell carcinoma taking single-agent pazopanib (800 mg daily), 27% experienced a partial response whereas approximately 46% were found to have stable disease at first analysis (33). These results were further confirmed in the recently reported phase III study in advanced renal cell carcinoma, where patients treated with pazopanib had a median progression-free survival of 9.2 months compared with 4.2 months for the placebo arm (32). In another smaller phase II trial of single-agent pazopanib (800 mg daily) in patients with advance ovarian, fallopian tube, or peritoneal carcinomas, 25% of the patients showed stable disease at >100 days after starting therapy (34). All of these studies report acceptable tolerability with minimal side effects from therapy. Together, these data suggest the feasibility of combining pazopanib with metronomic cytotoxic therapy.

In addition to the advantage of low toxicity with sustained “tumor cell kill,” metronomic dosing of cytotoxic agents has shown significant antiangiogenic properties partially secondary to increased endothelial cell apoptosis and decreased resistance (8, 9, 35). For example, Kamat and colleagues showed that metronomic taxane therapy alone and in combination with AEE788, a dual epidermal growth factor receptor and VEGFR, led to

Figure 5. Tumor cell proliferation and apoptosis analyses following in vivo therapy. A, Ki-67 staining in HeyA8 (left) and SKOV3ip1 (right) tumors following pazopanib and metronomic topotecan. B, representative photographs of Ki-67 staining in SKOV3ip1 tumors (original magnification ×100). Bars, SE. C, TUNEL analysis of tumor cell apoptosis in HeyA8 tumors. Bars, SD. *, P < 0.05 versus control. δ, P < 0.05 versus all other groups.
significant tumor growth inhibition and decreased tu-
mor angiogenesis in an orthotopic murine ovarian can-
cer model (6). Recently, we showed the antitumor ef-
cacy of oral metronomic topotecan in ovarian cancer
(10). Moreover, metronomic topotecan therapy led to
downstream target modulation of key proangiogenic
factors, VEGF and Hif-1α, resulting in decreased angio-
genesis and tumor growth in vivo (10); however, it does
not seem to affect VEGFR-2 phosphorylation. Here, we
report that pazopanib therapy resulted in antitumor and
antiangiogenic activity in preclinical models of ovarian
cancer. Moreover, when combined with topotecan, there
was substantial tumor growth inhibition and improve-
ment in survival of tumor-bearing mice. Previously,
we showed that metronomic and MTD dosing were
equally effective in reducing tumor growth; however,
metronomic therapy showed superior antiangiogenic ac-
tivity (10). Interestingly, metronomic therapy seemed
more efficacious compared with MTD therapy when
combined with pazopanib. Although a clear benefit
with the combination therapy was observed in all
models, differences in response to both single-agent
and combination therapy were observed. In support of
these data, Kerbel and colleagues report equivalent effi-
cacy using metronomic topotecan in combination with
pazopanib in an ovarian cancer model (36). In a recent
study, Rapisarda and colleagues also showed signifi-
cant antitumor and antivascular activity with combina-
tion therapy using an anti-VEGF antibody, bevacizumab,
with metronomic topotecan therapy (37). Indeed, most
VEGFR-targeted small molecule inhibitors and antibo-
dies result in increased systemic VEGF, which is consid-
ered in part to be a homeostatic response to overcome
receptor inhibition by increased ligand production. This
is most likely mediated by increased hypoxia due to in-
hibition of vascular permeability and angiogenesis by
VEGFR inhibitors (38). Our findings of decreased peri-
cyte coverage, thereby making the endothelium vulner-
able to antiangiogenic therapy, may further increase the
extent of hypoxia in the tumor microenvironment. The
decrease in pericyte coverage is expected given the anti-
PDGFR effects of pazopanib, and has been noted previ-
ously with targeting this pathway (39). Together, these
findings favor the selection of combining a Hif-1α inhibi-
tor in combination with an antiangiogenic agent targeting
VEGFR activity, such as pazopanib, given its mechanism
of action.

There are limited reports of metronomic therapy with
biological antiangiogenic agents. Klement and colleagues
reported that low-dose metronomic vinblastine therapy
with a VEGFR-2 inhibitor (DC101) decreased tumor ves-
sel formation and complete resolution of large neuro-
blastoma tumors in vivo (40). In a recent clinical trial,
bevacizumab and metronomic cyclophosphamide re-
sulted in a 24% overall response rate and survival of 17
months in patients with recurrent ovarian carcinoma (5).
The findings in the current study provide evidence that
metronomic therapy with pazopanib may provide a
unique therapeutic strategy for cancer patients, offering
potent antitumor activity with less treatment-delaying
toxicity.

The addition of biologically targeted agents and novel
cytotoxic regimens, such as metronomic therapy, begs
the question of whether preclinical and clinical studies
are accurately addressing tumor/host response. This
issue may directly impose limitations in accurately ass-
esing clinical and preclinical studies as presented here.
The “gold standard” of addressing tumor response has
been tumor measurement, usually by imaging studies,
and direct assessment of tumor weights and spread is
common practice in preclinical studies. Here, we present
a novel therapeutic regimen with a VEGFR inhibitor and
metronomic topotecan therapy. Based on tumor weight
alone, one of the two models showed significant tumor
growth inhibition when analyzing combination therapy
compared with other arms, but antiangiogenic activity
was significantly decreased in both models. Here, we
showed antiangiogenic activity using traditional mea-
surements of immunohistochemistry although we recog-
nize there are limitations and alternatives to this method
(41). Moreover, immunostaining analyses showed down-
stream effects on the tumor microenvironment, but these
methods may not be as accessible in patients receiving
biological agents. Serkova and colleagues recently pub-
lished a review discussing radiologic assessment of
treatment response in patients receiving novel cancer
therapies (42). They stressed the importance of exploring
newer protocols that can assess common end points of
targeted therapy, such as, angiogenesis, cell density,
proliferation, apoptosis, hypoxia, tumor perfusion, and
glucose uptake. Although not included in the current
study, we are currently investigating modalities that
may assist in addressing these end points of tumor re-
sponse in important pathways of cancer biology. These
differences may allow a better evaluation of treatment
response with not only antiangiogenic, but also other
novel biological agents in preclinical and clinical studies
in the future.

In summary, we have shown that oral pazopanib
therapy modulated VEGFR-2 activity in tumor and
endothelial cells in ovarian cancer models. Furthermore,
a novel therapeutic regimen utilizing oral metronomic
topotecan and pazopanib significantly reduced tumor
growth and angiogenesis, while prolonging animal sur-
vival. Changes in the tumor microenvironment with
combination therapy were shown by decreased tumor
cell proliferation and increased tumor cell apoptosis
in vivo. Decreased endothelial cell migration by pazopa-
nib and modulation of key angiogenic regulators by
metronomic topotecan therapy suggest this regimen is
highly active against tumor vasculature and warrants
evaluation in future clinical trials.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.
Grant Support

W.M. Merritt, Y.G. Lin, W.A. Spannuth, A.M. Nick, and R.L. Stone were supported by the National Cancer Institute (T32 Training Grant CA010642). M.M. Shahzad is supported by the GCP Molly-Cade ovarian cancer research grant and the NIH/NICHD Baylor WDRH scholarship (HD505128). Portions of this work were supported by U.T.M.D. Anderson Cancer Center SPORE in Ovarian Cancer (PS0 CA83639), the Marcus Foundation, the Entertainment Industry Foundation, the Blanton-Davis Ovarian Cancer Research Program, and the Betty Ann Asche Murray Distinguished Professorship to A.K. Sood.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 10/16/2009; revised 02/02/2010; accepted 02/09/2010; published OnlineFirst 04/06/2010.

References

Molecular Cancer Therapeutics

Bridging the Gap between Cytotoxic and Biologic Therapy with Metronomic Topotecan and Pazopanib in Ovarian Cancer


Updated version

Access the most recent version of this article at:
doi:10.1158/1535-7163.MCT-09-0967

Supplementary Material

Access the most recent supplemental material at:
http://mct.aacrjournals.org/content/suppl/2010/04/05/1535-7163.MCT-09-0967.DC1

Cited articles

This article cites 41 articles, 16 of which you can access for free at:
http://mct.aacrjournals.org/content/9/4/985.full.html#ref-list-1

Citing articles

This article has been cited by 9 HighWire-hosted articles. Access the articles at:
/content/9/4/985.full.html#related-urls

E-mail alerts

Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions

To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions

To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.